is jili178 legit

is jili178 legit It’s been a long road back to the highest levels of motorsport for Canadian driver Robert Wickens. Six years after he was paralyzed in a violent wreck, Wickens will again be behind the wheel against some of the best drivers in North America. Wickens, from Guelph, Ont., was named the newest driver for DXDT Racing earlier this week, moving the 35-year-old up to IMSA GTD competition for 2025, the highest class on the WeatherTech SportsCar Championship series. His promotion was made possible by a new hand control braking system created by Bosch Electronics, with help from GM Motorsports and Corvette Racing/Pratt Miller. “It’s not going to be easy but I wanted to get to the highest levels of motorsport again because, frankly, that’s where I was when I was injured,” said Wickens, who crashed at Pocono Raceway in 2018 during IndyCar’s ABC Supply 500. “But not only that, I want to prove to myself and other generations of people with disabilities that you can really do anything. “Maybe you’re having a hard time getting back to your place of work after a life-altering accident and — whatever your discipline, it doesn’t even have to be athletics — but I know it’s possible as long as you align yourself with a strong support system.” For Wickens, that’s been his wife Karli Wickens, his family and, in his professional life, organizations like Bosch and GM. Wickens’s crash left him with a thoracic spinal fracture, a neck fracture, tibia and fibula fractures to both legs, fractures in both hands, a fractured right forearm, a fractured elbow, four fractured ribs, a pulmonary contusion, and an indeterminate spinal injury that combined to make him a paraplegic. As he has slowly recovered some movement in his legs, Wickens has eased back into motor racing. He drove the parade lap of the 2019 Honda Indy Toronto, competed in the IndyCar iRacing Challenge during the early days of the COVID-19 pandemic, and then in January 2022 it was announced he would drive in the Michelin Pilot Challenge for Bryan Herta Autosport. He and co-driver Mark Wilkins won twice in the Michelin Pilot Challenge’s TCR category with three podiums in 2022. In 2023 the pairing didn’t win, but they reached the podium seven times to earn the TCR championship. All of Wickens’s post-accident cars have been fitted with hand controls. Those conventional systems rely on paddles around the steering wheel that activate pneumatics that then press the foot pedals. Hand controls like that are acceptable for regular road vehicles and even lower levels of motorsports but in the highest classes, like IMSA GTD where cars top out at more than 280 kilometres, the lag between the driver toggling the paddle and the car responding is unacceptably slow. That’s where the Bosch electronic system comes in, with the controls linked directly to the car’s braking system, removing the pneumatics as an intermediary. “When you hit the brakes to slow the car down for each corner that was always a big challenge for me where (with) the Bosch electronic system, the latency is milliseconds not tenths of a second,” said Wickens. “It’s basically as accurate as I would be if I was an able-bodied driver wanting to apply the brake. “Honestly, it’s just better in every facet imaginable. It’s just been a true blessing.” Advances in physical rehabilitation from spinal cord injuries as well as the ongoing development of vehicle technology has made Wickens’s return to competitive motorsport possible. “I’m very fortunate in the timing of my paralysis and my career,” Wickens said Wednesday from Tampa, Fla. “If this was even a decade ago we’d be having a very different conversation today.” The IMSA WeatherTech SportsCar Championship has four classes of vehicles: two sports prototype categories and two grand tourer classes. GTD is considered the highest of the four classes because each team must have at least a silver or bronze driver and more than one platinum-rated driver on a team is prohibited. “I want to win,” said Wickens. “I think the big thing for me on this journey back was I wanted to race again because I truly felt like I could still win. “I want to raise awareness for spinal cord injury and disability, not by just being a participant, but by being the guy. I want to win races, fight for podiums, win championships, every time I’m sitting in the car.” Wickens said he won’t just be a role model for people living with paralysis or other mobility disabilities, but the technology his car will employ in 2025 will likely become commercially available for use in road vehicles. “Motorsports and the automotive racing industry were founded to be a proving ground for everyday automotive vehicles,” he said. “From there you make road cars and road safety better. “Hopefully we can provide the technology and have regularly available components that can make any race car accessible for anyone that needs hand controls or any other form of disability.” This report by The Canadian Press was first published Nov. 27, 2024. Follow jchidleyhill.bsky.social on Bluesky. John Chidley-Hill, The Canadian Press

In the ever-evolving landscape of artificial intelligence (AI) development, new partnerships and collaborations are constantly emerging to push the boundaries of what is possible. One such recent alliance that has sparked considerable intrigue and speculation is the partnership between tech giant Amazon and AI startup Perplexity.Rat Chinese Horoscope 2025: Smart investments will lead to major gains

Manchester United's willingness to entertain offers for Rashford in the winter transfer window indicates that the club is keen to address its attacking issues sooner rather than later. With the team struggling to find goals and create chances on a consistent basis, the decision to potentially sell one of its most high-profile players reflects the urgency with which the club views the need for reinforcements. In doing so, United may be looking to free up funds and create space in the squad for new signings who can make an immediate impact.

Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis. According to GlobalData, Phase III drugs for Post Menopausal Osteoporosis have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Denosumab biosimilar overview Denosumab biosimilar (SB16) is under development for treatment of osteoporosis and prevention of skeletal related events with advanced malignancies and treatment of giant cell tumour of bone. The therapeutic candidate is a monoclonal antibody, which targets RANK ligand (RANKL). It is administered through subcutaneous route. Samsung Bioepis overview Samsung Bioepis, a subsidiary of Co Ltd, is a biopharmaceutical company. The company develops biosimilar products for immunology, oncology, ophthalmology, hematology, and endocrinology indications. It offers biological drugs for the treatment of Crohn’s disease, ulcerative colitis, psoriasis, cancer, and arthritis. The company is investigating SB12, an Eculizumab biosimilar targeting paroxysmal nocturnal hemoglobinuria; SB15, an Aflibercept biosimilar medicine against neovascular age-related macular degeneration; SB16, a denosumab biosimilar for the treatment of endocrinology disorders. Samsung Bioepis is also evaluating SB17, a Ustekinumab molecule against moderate to severe plaque psoriasis; and SB26 biosimilar to treat gastroenterology indications. Samsung Bioepis is headquartered in Incheon, Seoul, South Korea. For a complete picture of Denosumab biosimilar’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .

In the highly anticipated action-adventure game "Black Myth: Wukong," players are in for a treat as new gameplay mechanics have been revealed that will enhance the excitement of consecutive battles. One of the standout features is the introduction of new moves for the fearsome monsters that players will encounter, including the impressive Tiger Vanguard.

Don't Want Green Energy Jobs? We'll Take ThemIn a surprising turn of events, former Manchester United head of UK recruitment, Tony Ashworth, has emerged as a potential candidate for the vacant sporting director role at Arsenal. According to sources close to the club, Ashworth's impressive track record and expertise in player recruitment have caught the attention of the Arsenal hierarchy, who see him as a key figure in their ongoing restructuring efforts.

The issue of burden sharing within NATO is complex and multifaceted. It involves economic, political, and security considerations that must be carefully balanced. While President Trump's emphasis on fair payment is understandable, the question remains whether his tough rhetoric will ultimately lead to positive outcomes for the alliance.Kylian Mbappé, known for his lightning-fast pace and ability to stretch opposition defenses, was seen as a key player in executing this strategy. Mbappé's ability to time his runs and break through defensive lines made him the ideal candidate to take advantage of Barcelona's high defensive line. However, as the match unfolded, it became clear that things were not going according to plan.

Trans-rights debate front and center on Capitol HillIn conclusion, the possibility of Johny Srouji, the mastermind behind Apple's groundbreaking chips, taking on the role of CEO at Intel has generated immense interest and excitement within the tech community. His proven track record of innovation and success in the semiconductor industry makes him a compelling candidate to lead Intel into the next chapter of its evolution. Only time will tell if these speculations will come to fruition, but one thing is certain – wherever Johny Srouji goes, he is sure to leave a lasting impact on the world of technology.